Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 16/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 16/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.36 |
| ▸ | CDK1 | P06493 | 3/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10816708 | 0.80 | CDK2 (0.37) | CDK5CDK5R1CDK1CDK2CCNT1 | |
| SCHEMBL11096314 | 0.80 | CDK5 (0.38) | CDK5CDK5R1CDK1CDK2CCNE1 | |
| SCHEMBL10818020 | 0.79 | CDK5 (0.36) | CDK5CDK5R1CCNB2CDK1CCNB1 | |
| SCHEMBL9584828 | 0.78 | CCNB2 (0.40) | CCNB2CDK1CCNB1CCNB3P2RY1 | |
| SCHEMBL9594480 | 0.76 | HK1 (0.43) | CDK5CDK5R1CDK1CCNB1CDK2 | |
| SCHEMBL9583879 | 0.76 | ADORA2A (0.48) | KDM4E | |
| SCHEMBL10815977 | 0.76 | CDK5 (0.35) | CDK5CDK5R1 | |
| SCHEMBL9582816 | 0.75 | CDK1 (0.41) | CDK5CDK5R1CDK1CCNB1CDK2 | |
| SCHEMBL9584021 | 0.74 | CDK5 (0.33) | CDK5CDK5R1 | |
| SCHEMBL9583520 | 0.73 | CDK1 (0.43) | CDK5CDK5R1CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5250535-A | Herpes virus; nontoxic; side effect reduction; humans and veterinary medicine | SYNTEX INC. (US) | 1993-10-05 | — | — | US | disclosed |
| US-4803271-A | Process for preparing guanine derivatives | SYNTEX (U.S.A.) INC. (US) | 1989-02-07 | — | — | US | disclosed |
| US-4612314-A | Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl) purines as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1986-09-16 | — | — | US | disclosed |
| EP-0085424-A2 | Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1983-08-10 | — | — | EP | disclosed |